DBM-99H7

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NameDBM-99H7

Drug Alias Namedual acting CFTR potentiator/ENaC inhibitor (Discovery BioMed)cystic fibrosis therapeutics (Discovery BioMed)delF508-cystic fibrosis transmembrane conductance regulator correctors/potentiators (Discovery BioMed)DBM-99H7

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCystic fibrosis transmembrane conductance regulator stimulantsSodium channels blockers

TargetsCystic fibrosis transmembrane conductance regulatorSodium channels

Therapy Area/IndicationsCystic Fibrosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesDiscovery BioMed Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesDiscovery BioMed Inc

Active IndicationsN/A

Inactive IndicationsCystic Fibrosis

Other Information

ATC CodeN/A